390 related articles for article (PubMed ID: 28115470)
1. Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies.
Lang B; Makuch M; Moloney T; Dettmann I; Mindorf S; Probst C; Stoecker W; Buckley C; Newton CR; Leite MI; Maddison P; Komorowski L; Adcock J; Vincent A; Waters P; Irani SR
J Neurol Neurosurg Psychiatry; 2017 Apr; 88(4):353-361. PubMed ID: 28115470
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia.
Irani SR; Alexander S; Waters P; Kleopa KA; Pettingill P; Zuliani L; Peles E; Buckley C; Lang B; Vincent A
Brain; 2010 Sep; 133(9):2734-48. PubMed ID: 20663977
[TBL] [Abstract][Full Text] [Related]
3. Distinction between anti-VGKC-complex seropositive patients with and without anti-LGI1/CASPR2 antibodies.
Yeo T; Chen Z; Yong KP; Wong PYW; Chai JYH; Tan K
J Neurol Sci; 2018 Aug; 391():64-71. PubMed ID: 30103974
[TBL] [Abstract][Full Text] [Related]
4. Stop testing for autoantibodies to the VGKC-complex: only request LGI1 and CASPR2.
Michael S; Waters P; Irani SR
Pract Neurol; 2020 Oct; 20(5):377-384. PubMed ID: 32595134
[TBL] [Abstract][Full Text] [Related]
5. [Current Perspective on Voltage-gated Potassium Channel Complex Antibody Associated Diseases].
Watanabe O
Brain Nerve; 2018 Apr; 70(4):315-328. PubMed ID: 29632280
[TBL] [Abstract][Full Text] [Related]
6. Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex.
Montojo MT; Petit-Pedrol M; Graus F; Dalmau J
Neurologia; 2015 Jun; 30(5):295-301. PubMed ID: 24485651
[TBL] [Abstract][Full Text] [Related]
7. Voltage-gated potassium channel-complex autoimmunity and associated clinical syndromes.
Irani SR; Vincent A
Handb Clin Neurol; 2016; 133():185-97. PubMed ID: 27112678
[TBL] [Abstract][Full Text] [Related]
8. The value of LGI1, Caspr2 and voltage-gated potassium channel antibodies in encephalitis.
van Sonderen A; Petit-Pedrol M; Dalmau J; Titulaer MJ
Nat Rev Neurol; 2017 May; 13(5):290-301. PubMed ID: 28418022
[TBL] [Abstract][Full Text] [Related]
9. Detection of LGI1 and CASPR2 antibodies with a commercial cell-based assay in patients with very high VGKC-complex antibody levels.
Yeo T; Chen Z; Chai JYH; Tan K
J Neurol Sci; 2017 Jul; 378():85-90. PubMed ID: 28566186
[TBL] [Abstract][Full Text] [Related]
10. Insights from LGI1 and CASPR2 potassium channel complex autoantibody subtyping.
Klein CJ; Lennon VA; Aston PA; McKeon A; O'Toole O; Quek A; Pittock SJ
JAMA Neurol; 2013 Feb; 70(2):229-34. PubMed ID: 23407760
[TBL] [Abstract][Full Text] [Related]
11. Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies).
Bastiaansen AEM; van Sonderen A; Titulaer MJ
Curr Opin Neurol; 2017 Jun; 30(3):302-309. PubMed ID: 28248701
[TBL] [Abstract][Full Text] [Related]
12. The relevance of VGKC positivity in the absence of LGI1 and Caspr2 antibodies.
van Sonderen A; Schreurs MW; de Bruijn MA; Boukhrissi S; Nagtzaam MM; Hulsenboom ES; Enting RH; Thijs RD; Wirtz PW; Sillevis Smitt PA; Titulaer MJ
Neurology; 2016 May; 86(18):1692-9. PubMed ID: 27037230
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of voltage-gated potassium channel–complex antibodies in children.
Hacohen Y; Singh R; Rossi M; Lang B; Hemingway C; Lim M; Vincent A
Neurology; 2015 Sep; 85(11):967-75. PubMed ID: 26296514
[TBL] [Abstract][Full Text] [Related]
14. LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes.
Binks SNM; Klein CJ; Waters P; Pittock SJ; Irani SR
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):526-534. PubMed ID: 29055902
[TBL] [Abstract][Full Text] [Related]
15. Expanding spectrum of contactin-associated protein 2 (CASPR2) autoimmunity-syndrome of parkinsonism and ataxia.
Kannoth S; Nambiar V; Gopinath S; Anandakuttan A; Mathai A; Rajan PK
Neurol Sci; 2018 Mar; 39(3):455-460. PubMed ID: 29264691
[TBL] [Abstract][Full Text] [Related]
16. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series.
Lai M; Huijbers MG; Lancaster E; Graus F; Bataller L; Balice-Gordon R; Cowell JK; Dalmau J
Lancet Neurol; 2010 Aug; 9(8):776-85. PubMed ID: 20580615
[TBL] [Abstract][Full Text] [Related]
17. From VGKC to LGI1 and Caspr2 encephalitis: The evolution of a disease entity over time.
van Sonderen A; Schreurs MW; Wirtz PW; Sillevis Smitt PA; Titulaer MJ
Autoimmun Rev; 2016 Oct; 15(10):970-4. PubMed ID: 27485013
[TBL] [Abstract][Full Text] [Related]
18. Morvan syndrome: clinical and serological observations in 29 cases.
Irani SR; Pettingill P; Kleopa KA; Schiza N; Waters P; Mazia C; Zuliani L; Watanabe O; Lang B; Buckley C; Vincent A
Ann Neurol; 2012 Aug; 72(2):241-55. PubMed ID: 22473710
[TBL] [Abstract][Full Text] [Related]
19. Emerging psychiatric syndromes associated with antivoltage-gated potassium channel complex antibodies.
Prüss H; Lennox BR
J Neurol Neurosurg Psychiatry; 2016 Nov; 87(11):1242-1247. PubMed ID: 27435086
[TBL] [Abstract][Full Text] [Related]
20. Neuromyotonia and limbic encephalitis sera target mature Shaker-type K+ channels: subunit specificity correlates with clinical manifestations.
Kleopa KA; Elman LB; Lang B; Vincent A; Scherer SS
Brain; 2006 Jun; 129(Pt 6):1570-84. PubMed ID: 16613892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
